Edwards Lifesciences Reports Strong Q2 Results with TMTT Revenue Growth of 47%
On July 23, Edwards Lifesciences Corporation (NYSE:EW) reported second-quarter net sales of $1.74 billion, a year-over-year increase of 13.6%, surpassing the expected $1.70 billion. Adjusted diluted earnings per share rose to $0.78 from $0.67 in Q2 2025 and exceeded analyst estimates. The company's Transcatheter Mitral and Tricuspid Therapies (TMTT) segment saw a significant revenue jump of 47.3% year-over-year, reaching $195.9 million due to strong adoption of its next-generation structural heart devices. Edwards Lifesciences raised its full-year sales growth guidance for 2026 to between 10% and 11%, projecting revenue in the range of $6.6 billion to $6.9 billion, while reaffirming adjusted EPS guidance at $2.95 to $3.05. The company's TAVR segment also showed resilience with an 11.3% year-over-year increase in revenue and a revised full-year growth outlook of 8%-9%. Management is optimistic about the potential for Medicare coverage expansion, which could broaden patient eligibility and support procedure volumes. However, GAAP diluted EPS declined to $0.42 from $0.57 due to asset impairment charges and tax-related expenses. Skeptics are concerned over structural capacity limits in hospital cath labs and competitive pressures affecting pricing power.
Tickers: $EW
Topics: financial_performance healthcare structural_heart_devices TMTT